Literature DB >> 1527320

Relationships of bronchial responsiveness assessed by methacholine to serum IgE, lung function, symptoms, and diagnoses in 11-year-old New Zealand children.

B Burrows1, M R Sears, E M Flannery, G P Herbison, M D Holdaway.   

Abstract

The relationship of bronchial responsiveness (BR), assessed by methacholine challenge, to serum IgE, baseline ventilatory function, and symptoms or diagnoses suggesting an atopic disorder were examined in 522 11-year-old New Zealand children. BR was assessed by the presence or absence of a PC20 25 mg/ml or less and by calculating a continuous index of the decline of the FEV1 during the methacholine test. The latter facilitated multivariate analyses and revealed significant relationships to predictor variables even in those considered "nonresponsive" by PC20 criteria. There was a close relationship of BR to the baseline FEV1/vital capacity ratio, seen even in patients with known asthma, but this relationship was seen only in subjects with at least moderate levels of serum IgE. There was a less close relation of BR to percent predicted FEV1, but this persisted even after accounting for the FEV1/vital capacity ratio and was present regardless of the level of serum IgE. Reported asthma was associated with increased BR independent of all other factors, but other diagnoses and symptoms contributed relatively little to the prediction of BR once the serum IgE and lung function were taken into account. The overall results are compatible with the concept that IgE is a critical factor in the development of bronchial responsiveness in childhood.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1527320     DOI: 10.1016/s0091-6749(05)80018-1

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  20 in total

Review 1.  Methodology of bronchial responsiveness.

Authors:  S Chinn
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

Review 2.  Clinical effects of allergen avoidance.

Authors:  A Custovic; A Woodcock
Journal:  Clin Rev Allergy Immunol       Date:  2000-06       Impact factor: 8.667

3.  Measuring atopy in a multi-centre epidemiological study.

Authors:  S Chinn; D Jarvis; C M Luczynska; E Lai; P G Burney
Journal:  Eur J Epidemiol       Date:  1996-04       Impact factor: 8.082

Review 4.  Allergen avoidance in the treatment of asthma and atopic disorders.

Authors:  A Custovic; A Simpson; M D Chapman; A Woodcock
Journal:  Thorax       Date:  1998-01       Impact factor: 9.139

5.  Peak flow variability, methacholine responsiveness and atopy as markers for detecting different wheezing phenotypes in childhood.

Authors:  R T Stein; C J Holberg; W J Morgan; A L Wright; E Lombardi; L Taussig; F D Martinez
Journal:  Thorax       Date:  1997-11       Impact factor: 9.139

Review 6.  Childhood asthma: what is it and where is it going?

Authors:  G Christie; P Helms
Journal:  Thorax       Date:  1995-10       Impact factor: 9.139

7.  Evidence for two unlinked loci regulating total serum IgE levels.

Authors:  J Xu; R C Levitt; C I Panhuysen; D S Postma; E W Taylor; P J Amelung; K J Holroyd; E R Bleecker; D A Meyers
Journal:  Am J Hum Genet       Date:  1995-08       Impact factor: 11.025

8.  Activation of antiviral protein kinase leads to immunoglobulin E class switching in human B cells.

Authors:  K J Rager; J O Langland; B L Jacobs; D Proud; D G Marsh; F Imani
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

9.  Airway responsiveness to inhaled aspirin is influenced by airway hyperresponsiveness in asthmatic patients.

Authors:  Sungsoo Kim; Inseon S Choi; Yeon-Joo Kim; Chang-Seong Kim; Eui-Ryoung Han; Dong-Jin Park; Dae-Eun Kim
Journal:  Korean J Intern Med       Date:  2010-08-31       Impact factor: 3.165

10.  Effects of dehydroepiandrosterone on Th2 cytokine production in peripheral blood mononuclear cells from asthmatics.

Authors:  Inseon S Choi; Yong Cui; Young Ah Koh; Hyun Chul Lee; Yong Bum Cho; Young Ho Won
Journal:  Korean J Intern Med       Date:  2008-12       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.